US 11,667,711 B2
Anti-human LAG-3 antibodies and their use in immunohistochemistry (IHC)
Morten Draeby Sorensen, Herlev (DK); and Tine Hagedorn-Olsen, Skibby (DK)
Assigned to AGILENT TECHNOLOGIES, INC., Santa Clara, CA (US)
Filed by Agilent Technologies, Inc., Santa Clara, CA (US)
Filed on May 26, 2021, as Appl. No. 17/331,344.
Claims priority of provisional application 63/030,873, filed on May 27, 2020.
Prior Publication US 2021/0371520 A1, Dec. 2, 2021
Int. Cl. C07K 16/00 (2006.01); C07K 16/28 (2006.01); G01N 33/574 (2006.01)
CPC C07K 16/2803 (2013.01) [G01N 33/57492 (2013.01); C07K 2317/24 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/52 (2013.01); C07K 2317/56 (2013.01); G01N 2333/70503 (2013.01)] 22 Claims
 
1. A chimeric or a recombinant antibody (Ab) or an antigen binding fragment thereof capable of specifically binding to a human Lymphocyte-Activation Gene 3 (LAG-3) polypeptide, comprising:
a heavy chain variable region comprising:
the three CDR1, CDR2 and CDR3 complementarity determining regions (CDRs) of SEQ ID NO:2, or CDR1 amino acid (aa) residues 25-32, CDR2 aa residues 50-56, and CDR3 aa residues 95-101, of SEQ ID NO:2; and
a light chain variable region comprising:
the three CDR1, CDR2 and CDR3 complementarity determining regions (CDRs) of SEQ ID NO:3, or CDR1 amino acid (aa) residues 27-34, CDR2 aa residues 52-54, and CDR3 aa residues 91-102, of SEQ ID NO:3.